mAb Development

Jan 11, 2018
By BioPharm International Editors
Sartorius Stedim Biotech will equip Abzena’s contract development and manufacturing facilities in Bristol, PA, and San Diego, CA, with single-use equipment and scale-up technologies.
Jan 04, 2018
By BioPharm International Editors
The contract manufacturing company has completed construction on a new aseptic fill/finish facility in Wuxi, China.
Jan 01, 2018
BioPharm International
The authors present a robust and easy-to-implement chromatography column performance assessment method, called direct transition analysis (DTA).
Dec 20, 2017
By BioPharm International Editors
MilliporeSigma will collaborate with IPS and G-CON to offer end-to-end, turnkey, modular MAb manufacturing.
Dec 14, 2017
By BioPharm International Editors
FDA has approved a Pfizer biosimilar to J&J’s top-selling anti-inflammatory biologic, Remicade.
Dec 13, 2017
By BioPharm International Editors
The European Medicines Agency has granted Samsung BioLogics approval to manufacture a monoclonal antibody at the company’s second facility in Songdo, Incheon, South Korea.
Dec 11, 2017
By BioPharm International Editors
FDA has accepted for review Eli Lilly and Company’s biologic drug candidate that is in development for treating migraine.
Dec 08, 2017
By BioPharm International Editors
The new 30,000-L, $150-million biologics manufacturing facility in Wuxi, China, quintuples the company’s existing manufacturing capability.
Nov 29, 2017
By BioPharm International Editors
Binding Site has introduced a number of new monoclonal antibodies targeting infectious diseases, including cytomegalovirus, hepatitis (A, B, C, and D), herpes, human immunodeficiency virus (HIV), rubella, and toxoplasma.
Nov 28, 2017
By BioPharm International Editors
The acquisition gives GE Healthcare access to a nanofiber-based platform purification technology that can offer improvements in biopharmaceutical productivity.
native1_300x100
lorem ipsum